Overview

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Teclison Ltd.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab